Approved medicines Human trials in product label Sexual health
Also discussed as: Vyleesi, PT141
What it is and how it works
Bremelanotide is a melanocortin receptor agonist. The Vyleesi label explains that the precise mechanism by which it improves the labeled condition is not known. A receptor target can be identified even when the complete clinical mechanism remains uncertain.
Source for the mechanism context →A closer look at the cited evidence
Human trials in product label
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- DailyMed — Vyleesi clinical studies and mechanism
- Design
- Two randomized, double-blind, placebo-controlled studies summarized in the label.
- Who or what was studied
- Premenopausal women with acquired, generalized hypoactive sexual desire disorder meeting the study criteria.
- What was observed
- Study endpoints included sexual desire and related distress; the label describes the results and limits.
- Limits of interpretation
- These outcomes do not establish a universal libido benefit, an indication in men, or enhancement of sexual performance.
What the evidence means
Evidence for its labeled use does not establish a general libido or performance benefit.
Approval and regulatory context
Vyleesi is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women meeting the labeled criteria; it is not indicated to enhance sexual performance.
Safety and uncertainty
The label addresses nausea, blood-pressure increases, and hyperpigmentation. It is contraindicated with uncontrolled hypertension or known cardiovascular disease.
What remains uncertain
Sexual symptoms can have different medical, medication-related, psychological, and relationship contexts. This profile cannot identify their cause. A PT-141 research product also cannot be assumed equivalent to the approved medicine.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.